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(€5,671.00) annual costs per patient were calculated. 
Pharmacy costs (€4,032.73) were highest among overall 
expenditures, followed by additional AS-related consulta-
tion (€2,480.38), outpatient (€225.02), and inpatient costs 
(€29.98). Over half of AS patients (54.8 %) experienced 
work loss. Related average annual costs were €414.16, 
based on income level. 10.3 % of AS patients incurred an 
additional €2,008.07 in 1 year. 6.8 % of patients required 
caregivers and incurred €778.70 in average annual patient 
paid costs. Mean Pt-GDA, Pain-VAS, EQ-5D, BASDAI, 
BASFI, and BASMI scores were 4.4, 40.5, 62.7, 3.6, 3.1, 
and 2.9, respectively. Direct and indirect AS-related costs 
are high and represent a considerable economic burden on 
Turkish AS patients.
Keywords Ankylosing spondylitis · Direct costs · 
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Abstract This study assessed quality of life, direct and 
indirect healthcare costs related to ankylosing spondylitis 
(AS). This study included 650 prevalent AS patients visit-
ing seven centers at tertiary healthcare institutions in Tur-
key who were interviewed using a standard questionnaire 
to determine annual direct and indirect healthcare costs. 
Eligible patients were age ≥18 years with AS for at least 
12 months. Direct costs were categorized as inpatient, out-
patient and pharmacy, and AS-related consultation. Indi-
rect costs were categorized as workday loss, additional 
AS-related costs, and caregiver costs. Clinical outcome 
measures were obtained, including Patients’ Global Dis-
ease Activity (Pt-GDA); visual analog scale (Pain-VAS) for 
pain; Bath Ankylosing Spondylitis Disease Activity Index 
(BASDAI), Functional Index (BASFI), and Metrology 
Index (BASMI) scores, and EuroQoL 5 dimension (EQ-5D) 
health status survey scores. Mean (€4,335.20) and median 
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Introduction
Ankylosing spondylitis (AS) is a chronic, systematic, and 
inflammatory rheumatic disease that primarily affects the 
axial skeleton and can lead to structural and functional 
impairments, low productivity, decrease in life quality, and 
substantial healthcare resource use [1]. Clinical features of 
AS include back pain, stiffness, asymmetrical peripheral 
oligoarthritis, and specific organ involvement such as ante-
rior uveitis, psoriasis, and chronic inflammatory bowel dis-
ease [2].
Approximately, 80 % of patients develop their first 
symptoms before age 30 and less than 5 % develop AS 
when they are over age 45. Men are more likely to be 
affected compared to women at an approximate 2:1 ratio 
[3]. Also, juvenile-onset AS is usually associated with 
worse outcomes than adult-onset AS [4]. Reported AS 
prevalence ranges between 0.1 and 0.8 %, and recent stud-
ies suggest that prevalence is actually closer to 0.5 % in 
European populations, especially in Northern Europe [5]. 
Surveys have estimated AS prevalence in the Turkish adult 
population at 0.49 % [6].
Traditionally, the “gold standard” of AS treatment is 
non-steroidal anti-inflammatory drugs (NSAIDs), which 
improve inflammatory symptoms of AS including the 
inflammatory back pain. Furthermore, gastrointestinal com-
plications are a common side effect of NSAIDs [7]. Dis-
ease-modifying antirheumatic drugs (DMARDs), including 
sulfasalazine, methotrexate, and leflunomide, though not 
proven effective, are widely used in some countries as a 
secondary treatment approach for patients who are refrac-
tory to NSAID treatment.
In recent years, anti-tumor necrosis factor alpha (TNFα) 
use has been studied extensively and has been shown to 
provide significant clinical benefits for AS patients. Avail-
able TNFα inhibitors are infliximab, adalimumab, etaner-
cept, golimumab, and certolizumab. These drugs strongly 
suppress inflammation [8].
Prior to development of efficacious biologics, overall 
treatment costs were low in AS patients. Annual estimates 
included €2,335 in the Netherlands, €2,064 in France, 
€1,572 in Belgium, and €1,750 in the United States [7, 
9]. However, availability of improved but expensive treat-
ment options required the need for information concerning 
the current disease burden. Many recent studies have been 
implemented around the world to estimate the economic 
burden of AS per patient in different countries. In the 
United Kingdom, total annual direct costs per patient were 
calculated at £15,973 [10]. In Spain, the total mean annual 
cost per patient was estimated at €20,328, with direct costs 
accounting for 22.8 % [11]. In Canada, the mean annual 
cost per patient was $9,008 Canadian dollars (€7,383), of 
which direct healthcare costs represented 62.0 %, or $5,585 
(€4,578) [12]. In Hong Kong, total annual costs were calcu-
lated at €7,045, of which direct costs accounted for 38.0 % 
[13].
The economic burden of AS in Turkey is not well docu-
mented. This study aimed to examine AS patient charac-
teristics and the economic impact of the disease. In this 
respect, the study objectives were to evaluate AS patient 
demographic and clinical characteristics, examine patient 
work environment and prescribed medication types, esti-
mate direct and indirect costs of AS, and determine the 
association between cost and disease activity score. The 
present study also aimed to highlight the significance of 
the economic burden of AS inform policy decision makers 
to better accommodate Turkish employees diagnosed with 
AS.
Methods
In the present noninterventional, cross-sectional study, 
information was collected directly from patients through 
a questionnaire distributed to seven university hospitals, 
tertiary healthcare centers in Turkey. All subjects were at 
least age 18 years, with an AS diagnosis for a minimum of 
12 months. Patients were interviewed in a single visit dur-
ing the 1-year study period from May 2011 through August 
2012. Patients were interviewed regarding demographic 
information (age, gender, and region), AS-related health-
care services including rheumatologic care, prescription 
medications, rehabilitative therapies, diagnostic and thera-
peutic procedures (including complementary therapies), 
inpatient hospitalization, and medications used during hos-
pitalization, comorbid conditions (heart disease, diabetes), 
medication use (DMARDs, non-selective Cox inhibitors) 
during the 3-month pre-index period, as well as expendi-
tures for medical devices, caregiver needs, and work capac-
ity (sick leave days).
Clinical outcome measures were collected for Patients’ 
Global Disease Activity (Pt-GDA) assessment, EuroQoL 
5 dimension (EQ-5D) health status survey, pain score on 
VAS, Bath Ankylosing Spondylitis Disease Activity Index 
(BASDAI) [14], Bath Ankylosing Spondylitis Functional 
Index (BASFI) [15], and the Bath Ankylosing Spondyli-
tis Metrology Index (BASMI) [16]. Pt-GDA, BASDAI, 
BASFI, and BASMI results are measured on a scale of 
0–10, where higher scores indicate higher disease activ-
ity. EQ-5D and pain scores were measured on a VAS of 
0–100 mm. High pain VAS, BASDAI, and BASFI scores 
indicate higher pain severity, and higher EQ-5D scores 
indicate better quality of life.
Total direct medical costs were calculated as the sum-
mation of inpatient, outpatient, pharmacy costs, and other 
AS-related interventions (e.g., acupuncture, homeopathic, 
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other). Total indirect costs were calculated as the sum of 
those due to work loss, caregiver, and other expenses such 
as new car, apartment, or special equipment purchases 
due to AS. Annual costs for outpatient care and pharmacy, 
work loss, caregiver, and any consultation expenses that are 
not covered by social insurance were calculated by multi-
plying 3-month data by four, and data for additional AS-
related investments were collected for 1-year period. For 
work loss, income ranges were taken into account, and the 
human capital approach was used. The direct and indirect 
costs were expressed per year. All costs were expressed in 
2011 euros (€1.00 = 2.3 Turkish Liras, without inflation 
adjustment).
Univariate statistics for demographic and clinical varia-
bles were created for descriptive analysis. Continuous vari-
ables were summarized by providing the number of obser-
vations, mean and standard deviation (SD), and median 
(minimum–maximum). Numbers and percentages are pro-
vided for dichotomous and polychotomous variables. Chi-
square test was used to compare categorical variables. All 
statistical analyzes were conducted using SAS v.9.3 and 
STATA v11 software.
Results
After applying all inclusion criteria, the analytic sample 
included 648 patients. Mean patient age was 40.5 years, 
and 98.6 % of them were under age 65 years. Almost one-
third of the patients were women. Average disease dura-
tion was 7.7 years. Nearly, 8 % of the study subjects were 
diagnosed with at least one of the following comorbid con-
ditions: heart disease, diabetes, respiratory disease, aller-
gies, Crohn’s disease, uveitis, or rheumatoid arthritis. Of 
the patients, 7.5 % were hospitalized, 3.5 % were in reha-
bilitation services, 2.1 % underwent surgery, and 1.2 % had 
prosthesis (Table 1).
Interestingly, the percentage of female patients who 
were prescribed biologic agents was lower than for male 
patients. In addition, average Pt-GDA, Pain-VAS, BASDAI, 
and BASFI scores were found to be significantly lower in 
males than in females, whereas EQ-5D and BASMI scores 
were similar (Table 2).
Most patients were prescribed biologic agents, 
DMARDs, and NSAIDs (66.5, 50.5, and 37.7 %), followed 
by gastrointestinal-related medications such as proton 
pump inhibitors, histamine h2-receptors (28.9 %), and glu-
cocorticoids (10.34 %) (Table 3).
Table 4 shows the direct and indirect costs related with 
AS. Average annual healthcare costs for AS patients were 
calculated at €4,335.20. The most significant share of over-
all expenditures consisted of pharmacy costs (€4,032.73), 
Table 1  Demographic and clinical characteristics of the study par-
ticipants
SD standard deviation, DMARDs disease-modifying antirheumatic 
drugs
All patients n = 648
Age, mean (SD) 40.6 (11.4)
 ≤65 years, n (%) 639 (98.6)
 >65 years, n (%) 9 (1.4)
Sex (female), n (%) 231 (35.7)
Pre-index comorbid conditions, n (%)
 Uveitis 49 (7.6)
 Heart disease 33 (5.1)
 Diabetes 31 (4.8)
 Allergy 26 (4.1)
 Respiratory disease 22 (3.4)
 Crohn’s disease 21 (3.2)
 Rheumatoid arthritis 13 (2.1)
Disease duration, years, mean (SD) 7.7 (7.4)
Symptom duration, years, mean (SD) 5.7 (6.3)
Table 2  Clinical variables related to disease burden
Data are presented as mean (SD)
Pt-GDA global disease activity, VAS visual analog scale, BASDAI 
bath ankylosing spondylitis disease activity index, EQ-5D euroQol 
health status, BASFI bath ankylosing spondylitis functional index, 
BASMI bath ankylosing spondylitis metrology index
Entire popula-
tion (n = 648)
Female 
(n = 231)
Male (n = 417)p value
Pt-GDA 4.4 (2.2) 4.7 (2.1) 4.2 (2.2) 0.0039
Pain-VAS 40.5 (24.1) 45.7 (23.2) 37.6 (24.1) <0.0001
BASDAI 3.6 (2.2) 4.2 (2.2) 3.2 (2.1) <0.0001
BASFI 3.1 (2.5) 3.5 (2.4) 2.9 (2.5) 0.0034
BASMI 2.9 (2.6) 2.6 (2.3) 3.1 (2.8) 0.0610
EQ-5D 0.63 (20.5) 0.61 (19.6) 0.64 (20.9) 0.0710
Table 3  Medication use for ankylosing spondylitis patients during 
the 3-month pre-index period
DMARD disease-modifying antirheumatic drug, NSAI non-steroidal 
anti-inflammatory
All patients, (n = 648)
n (%)
Biologic agents 431 (66.5)
DMARDs 327 (50.5)
NSAI agents 244 (37.7)
NSAI topical agents 131 (20.2)
Paracetamol 17 (2.6)
Glucocorticoids 67 (10.3)
Gastroprotective agents 187 (28.9)
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followed by AS-related consultations (€2,480.38), outpa-
tient (€225.02), and inpatient costs (€29.98) (Table 4). A 
minority of patients (2 %) had other AS-related therapies 
not covered by social insurance (acupuncture, homeopathy, 
other), bringing their average annual burden to €2,480.38. 
Indirect AS-related costs due to work loss, additional AS-
related costs, and caregiver costs were evaluated (Table 4). 
Nearly, 55 % of AS patients were employed, of which 
59.4 % had sick leave with the permission of the employer, 
costing an average of €414.16 annually due to workday 
loss. Nearly, one-tenth of AS patients incurred additional 
AS-related costs (e.g., need for new car, apartment, special 
equipment) at €2,008.07 in 1 year. The utilization of health 
caregivers and the average annual out-of-pocket cost for 
caregivers was €778.70 (Table 4).
Discussion
A variety of studies in the United States and Europe exist 
evaluating the economic burden and prevalence of AS. Epi-
demiologic studies have indicated that AS is more preva-
lent than previously thought [17]. Prevalence of AS as well 
as its economic burden have been studied only in a limited 
number of studies in Turkey [6, 18, 19]. Thus, the current 
study is designed to thoroughly examine AS patient charac-
teristics and the economic impact of the disease in Turkey.
The most significant strength of this study is that it was 
performed using real-world data. No previously published 
studies include such data. A recent study by Malhan et al. 
[20] examined direct and indirect costs of AS patients in 
Turkey, which was limited because the data were gath-
ered from an expert panel. Although an expert panel is a 
relatively inexpensive and rapid tool to produce a synthetic 
judgment based on qualitative and quantitative data, it has 
some limitations. Comparing opinions often leads to under 
evaluation of lesser known or underreported points of 
view. It represents the consensus of panel attendants rather 
than real-world outcomes [21, 22]. Total direct medical 
costs per patient differ significantly between the study by 
Malhan et al. [20] and this study (€3,566 and €4,335.20, 
respectively).
In addition to direct medical costs, AS patients in Tur-
key experienced work productivity loss, contributing to the 
total economic burden. Average annual workday losses in 
our study (€414.16) exceeded the estimate by Malhan et al. 
[20] (€245.50). According to Boonen et al. [23], patients 
in France (n = 53) had adjusted productivity losses (using 
the friction method) totaling €428 per year, and patients in 
Belgium (n = 26) and the Netherlands (n = 130) experi-
enced adjusted productivity losses of €476 and €1,257, 
respectively. Adjusted work disability was 23 % in France, 
9 % in Belgium, and 41 % in the Netherlands. In a more 
recent study conducted by Kvamme et al. [24], annual 
adjusted productivity loss, using the friction method, for 
hospitalized patients in the Netherlands reached €7,686 for 
synthetic DMARD use (n = 49) and €8,186 for biologic 
DMARD use (n = 137). The variation in work status and 
productivity costs observed in European countries suggests 
that economic generalizability may be limited. This under-
scores the importance of conducting health economic stud-
ies specific to the country of interest for the effective allo-
cation of resources and other healthcare applications. Other 
indirect cost measures in our research included AS-related 
complementary therapies and additional costs, as well as 
out-of-pocket costs for caregiver utilization. These varia-
bles were not assessed in the previous studies from Turkey.
The present study is unique in that it uses real-world data, 
assesses variables not previously examined in other studies 
and includes a thorough analysis of nationally representative 
direct and indirect costs of AS in Turkey. It should be noted 
that all patients were diagnosed at tertiary medical centers, 
which may explain the unexpectedly high proportion of AS 
patients receiving biologic therapy, which may be considered 
as a limitation of the study. It should be noted that use of 
biologic therapy was less prevalent among female patients 
than among male patients. That is most probably due to the 
relatively common presence of fibromyalgia accompanying 
Table 4  Annual average direct 
and indirect costs of ankylosing 
spondylitis
AS ankylosing spondylitis, 
SD standard deviation, IQR 
interquartile range
n Annual average costs (SD) Median (IQR, 25th–75th percentile)
Direct costs
 Inpatient €29.98 (€119.51) €0.00 (0.0–8.0)
 Outpatient €225.02 (€190.28) €166.33 (92.0–245.0)
 Pharmacy €4,032.73 (€2,723.55) €5,426.56 (1204.0–6225.0)
 AS-related consultations €2,480.38 (3,479.18) 539 (209.0–3043.0)
 Total 648 €4,335.20 (€2.891,74) €5,671.00 (1370.0–6451.0)
Indirect costs
 Additional AS-related costs 67 €2,008.07 (7,376.04) 87 (20.0–435.0)
 Caregiver 44 €778.70 (1,179.01) 522 (278.0–870.0)
 Workday loss 355 €414.16 (1,313.35) 104 (0.0–319.0)
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AS in female patients, which negatively affects disease activ-
ity and functional scores as previously reported [25]. It might 
have been also due to differences in socioeconomic status. It 
has been shown that groups with lower socioeconomic status 
seem to have less access to biologic medications, in terms 
of lower availability, affordability, and acceptability. More 
barriers that may have resulted in worse disease course in 
female patients [26]. More hospitalized patients were admin-
istered infliximab, possibly because the medication was dis-
pensed via percutaneous infusion, which is a possible weak-
ness of the present study.
Our results also indicated higher disease activity scores 
among female patients compared to males. Previous studies 
have also shown that there are gender differences regarding 
autoimmune disease characteristics, with women scoring 
higher on pain and quality of life measurement scales [27, 
28]. However, these scores were considered higher subjec-
tively and not objectively, suggesting that disease activity 
may have been discounted in the treatment decision.
AS has significant economic implications for individuals 
and society. Yet for Turkey, the cost of care has not been 
analyzed using real-world clinical data. This study also 
demonstrated that indirect AS-related costs in Turkey are 
significant. The young age of patients who reported sick 
leave reveals the negative effect of AS on national econ-
omy. For this reason, indirect cost should be taken into con-
sideration during Payor’s decision making process. Moreo-
ver, future comparative effectiveness studies concerning AS 
treatment should include direct and indirect costs.
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